Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11475295 | 0.77 | ALDH1A1 (0.37) | TRPA1ALDH1A1 | |
| SCHEMBL3273808 | 0.74 | MGAM (0.42) | ALDH1A1 | |
| SCHEMBL409706 | 0.74 | — | — | |
| SCHEMBL27684403 | 0.74 | TSHR (0.30) | — | |
| SCHEMBL10690402 | 0.74 | — | — | |
| SCHEMBL17494846 | 0.73 | — | — | |
| SCHEMBL6217611 | 0.73 | TRPA1 (0.30) | TRPA1ALDH1A1 | |
| SCHEMBL1574455 | 0.72 | — | — | |
| SCHEMBL18691826 | 0.72 | — | — | |
| SCHEMBL8290885 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831942-B | Fused indazolopyridinone compounds as antiviral agents | 诺华股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3998269-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3615533-B1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| CN-110831942-A | Fused indazolopyridinone compounds as antiviral agents | 诺华股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20180312507-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | TRPA1 4478/4885ALDH1A1 1956/4885 |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | TRPA1 4478/4885ALDH1A1 1956/4885 |
| US-20180312507-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | TRPA1 4478/4885ALDH1A1 1956/4885 |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | CYP3A5, CYP3A43, CYP3A4 | TRPA1 4478/4885ALDH1A1 1956/4885 |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | CYP3A5, CYP3A43, CYP3A4 | TRPA1 4478/4885ALDH1A1 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.